Home Office

PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number]

Establishment Licence name	Designated area within the University of Cambridge, Anne Maclaren Building
Establishment Licence number	X81BD37B1
Name of PPL holder	Brian Huntly
PPL number	PP3042348 (Huntly) Investigation of normal haematopietic stem cell subversion and the evolution, maintenance and targeting of haematological malignancies
Protocol no	7
Protocol title	[Moderate] 07 Study of the impact of cell extrinsic factors on normal, pre-malignant and malignant haematopoiesis through transplantation (Mice)

Severity classification	Moderate
1. Date of incident	02/07/21
2. Species	Mouse
3. Brief details of study and how the limits or constraints have been breached	On 19/04/21 lethally irradiated mice were transplanted with a murine lymphoma cell line (study plan SP096848). The mice were checked twice daily and bled once a week to monitor disease development. On 02/07/21 one mouse was found dead. Post-mortem analysis confirmed they had succumbed to lymphoma.
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	N/A
5. Cause of Problem, if known	Mouse died of lymphoma.
6. Action that has been or will be taken *(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)*	Unfortunately, some of the lymphoma models that we work with deteriorate very rapidly once they succumb to disease and determining the end-point using clinical signs alone can be very difficult. Since we are bleeding the mice weekly we now plan to use blood parameters (such as haemoglobin levels) to determine the end-point. We have found low haemoglobin levels across mice that we have sacrificed with overt disease in the past and we believe that this is a more consistent indicator of overt disease than white cell count which can vary quite considerably according to the tumour transplanted. We propose that a haemoglobin count of less than 10 g/dl and / or clinical signs including decreased activity, panting and hunching in the corner after activity (e.g when the cage is closed again after opening for checks) are the humane end-points.
7. Reported by (name)	Sarah Horton/Ryan Asby
8. Date	02/07/21

**********For official use**********

Inspector's comments and recommendations:

Comments and recommendations	One mouse found dead on 2/7/21 thereby exceeding severity; cause of death was confirmed by post-mortem as lymphoma. Current humane end points include signs of ill health that persist for more than 24 hours. Licence holder will use earlier (clinical signs after activity) and more specific (reduced haemoglobin) end points to reduce risk of recurrence in future.
Inspector name	John F Marshall
Date	06/07/21